Effect of Type 2 Diabetes Mellitus and Hypertension on Quality of Life: A Cross-Sectional Study

  • Simran Goel M.M. College of Pharmacy, Maharishi Markandeshwar (Deemed to be) University, Mullana, Ambala, HR, India
  • Sristi Anupam M.M. College of Pharmacy, Maharishi Markandeshwar (Deemed to be) University, Mullana, Ambala, HR, India
  • Karun Bhatti Department of Medicine, M.M. Institute of Medical Sciences and Research, Maharishi Markandeshwar (Deemed to be) University, Mullana, Ambala, HR, India
  • Dinesh Kumar Mehta M.M. College of Pharmacy, Maharishi Markandeshwar (Deemed to be) University, Mullana, Ambala, HR, India
  • Rina Das MM College of Pharmacy, MMDU, Mullana
DOI: https://doi.org/10.5937/scriptamed56-52070
Keywords: Diabetes mellitus, type 2, Hypertension, Insulin resistance, Quality of life, Blood pressure, Blood glucose

Abstract


Background/Aim: The quality of life (QOL) of the person is shown to be severely impacted by conditions such as type 2 diabetes mellitus (T2DM) and hypertension. Aim of this study was to investigate how both these conditions affect QOL of patients dealing with those conditions. 

Methods: A total of 276 participants were divided into three groups: T2DM (45.00 %), hypertension (14.75 %) and both conditions (40.25 %). The analysis included monitoring blood pressure and blood sugar levels. Participants completed a health quality evaluation questionnaire and data were expressed as mean ± standard deviation. 

Results: The results indicated that the duration of these diseases significantly impacted individuals' health. Physically, women were more adversely affected (12 %) than men (9.2 %) across all groups. Additionally, participants with mixed diets and both conditions experienced more negative effects (10.86 %) compared to vegetarians (6.25 %). It was found that individuals with T2DM and hypertension concurrently had a considerably lower QOL compared to those without these conditions. 

Conclusions: The study highlights that the type of diet and the duration of the disease significantly influence the QOL of patients. These factors were found to have a substantial impact on the overall well-being of individuals with T2DM and hypertension.

References

Svalastog AL, Donev D, Kristoffersen NJ, Gajović S. Concepts and definitions of health and health-related values in the knowledge landscapes of the digital society. Croat Med J. 2017;58(6):431-5. doi: 10.3325/cmj.2017.58.431.

Reeve B. International Society for Quality of Life Research (ISOQOL). In: Michalos AC. (Eds). Encyclopedia of Quality of Life and Well-Being Research. Dordrecht, NA: Springer, 2014. pp. 3330-3331. doi: 10.1007/978-94-007-0753-5_1508.

Kirkman MS, Briscoe VJ, Clark N, Florez H, Haas LB, Halter JB, et al. Diabetes in older adults. Diabetes Care. 2012 Dec;35(12):2650-64. doi: 10.2337/dc12-1801.

Glasgow RE, Osteen VL. Evaluating diabetes education: Are we measuring the most important outcomes? Diabetes Care. 1992;15(10):1423-32. doi:10.2337/diacare.15.10.1423.

Garg P, Duggal N. Type 2 diabetes mellitus, its impact on quality of life and how the disease can be managed-a review. Obes Med. 2022;35:67-79. doi: 10.1016/j.obmed.2022.100459.

Lloyd A, Sawyer W, Hopkinson P. Impact of long-term complications on quality of life in patients with type 2 diabetes not using insulin. Value Heal. 2001;4(5):392-400. doi: 10.1046/j.1524-4733.2001.45029.x.

Bin Rakhis SA, AlDuwayhis NM, Aleid N, AlBarrak AN, Aloraini AA. Glycemic control for type 2 diabetes mellitus patients: a systematic review. Cureus. 2022:118-229. doi: 10.7759/cureus.26180.

Bratke H, Biringer E, Margeirsdottir HD, Njølstad PR, Skrivarhaug T. Relation of health-related quality of life with glycemic control and use of diabetes technology in children and adolescents with type 1 diabetes: results from a national population based study. J Diabetes Res. 2022;2022:117-28. doi: 10.1155/2022/8401328.

Svedbo Engström M, Leksell J, Johansson UB, et al. Health-related quality of life and glycaemic control among adults with type 1 and type 2 diabetes - A nationwide cross-sectional study. Health Qual Life Outcomes. 2019;17(1):225-39. doi:10.1186/s12955-019-1212-z.

Jacobson AM. Impact of improved glycemic control on quality of life in patients with diabetes. Endocr Pract. 2004;10(6):502-8. doi: 10.4158/EP.10.6.502.

Billings LK, Handelsman Y, Heile M, Schneider D, Wyne K. Health-related quality of life assessments with once-weekly glucagon-like peptide-1 receptor agonists in type 2 diabetes mellitus. J Manag Care Spec Pharm. 2018;24(9):S30-S41. doi: 10.18553/jmcp.2018.24.9-a.s30.

Klein R, Moss SE, Klein BEK, Gutierrez P, Mangione CM. The NEI-VFQ-25 in people with long-term, type 1 diabetes mellitus: The wisconsin epidemiologic study of diabetic retinopathy. Arch Ophthalmol. 2001;119(5):733-740. doi: 10.1001/archopht.119.5.733.

Hänninen J, Takala J, Keinänen-Kiukaanniemi S. Quality of life in NIDDM patients assessed with the SF-20 questionnaire. Diabetes Res Clin Pract. 1998;42(1):17-27. doi: 10.1016/S0168-8227(98)00085-0.

Glasgow RE, Ruggiero L, Eakin EG, Dryfoos J, Chobanian L. Quality of life and associated characteristics in a large national sample of adults with diabetes. Diabetes Care. 1997;20(4):562-7. doi: 10.2337/diacare.20.4.562.

Wändell PE. Quality of life of patients with diabetes mellitus: An overview of research in primary health care in the Nordic countries. Scand J Prim Health Care. 2005;23(2):68-74. doi: 10.1080/02813430510015296.

Zhang JT, Chen KP, Guan T, Zhang S. Effect of aliskiren on cardiovascular outcomes in patients with prehypertension: A meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2015;9:1963-71. doi: 10.2147/DDDT.S75111.

Mena-Martin FJ, Martin-Escudero JC, Simal-Blanco F, Carretero-Ares JL, Arzua-Mouronte D, Herreros-Fernandez V. Health-related quality of life of subjects with known and unknown hypertension: Results from the population-based Hortega study. J Hypertens. 2003;21(7):1283-9. doi: 10.1097/00004872-200307000-00015.

Soni RK, Porter AC, Lash JP, Unruh ML. Health-related quality of life in hypertension, chronic kidney disease, and coexistent chronic health conditions. Adv Chronic Kidney Dis. 2010;17(4). doi: 10.1053/j.ackd.2010.04.002.

Ware JE. SF-36 Health survey update. Spine (Phila Pa 1976). 2000;25(24):3130-9. doi: 10.1097/00007632-200012150-00008.

Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992 Jun;30(6):473-83. PMID: 1593914.

Nakanishi N, Suzuki K, Tatara K. Serum γ-glutamyltransferase and risk of metabolic syndrome and type 2 diabetes in middle-aged Japanese men. Diabetes Care. 2004;27(6):1427-32. doi: 10.2337/diacare.27.6.1427.

Sattar N, Scherbakova O, Ford I, et al. Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the West of Scotland Coronary Prevention Study. Diabetes. 2004;53(11):2855-60. doi: 10.2337/diabetes.53.11.2855.

Published
2025/02/28
Issue
Vol. 56 No. 1 (2025): Jan-Feb
Section
Original article
Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).